Table 2 EZH2 expression in breast carcinoma and relationship with clinicopathologic characteristics
Clinicopathologic features | EZH2 score | |||
|---|---|---|---|---|
Total N (%) | <3 score, negative | >3 score, positive | P value | |
Age at diagnosis (year) | ||||
<50 | 133 | 36.8 % (49/133) | 63.2 % (84/133) | p > 0.05 |
≥50 | 93 | 41.9 % (39/93) | 58.1 % (54/93) | |
Menopausal status | ||||
Premenopausal | 125 | 36 % (45/125) | 64 % (80/125) | p > 0.05 |
Postmenopausal | 101 | 42.6 % (43/101) | 57.4 % (58/101) | |
Estrogen receptor status | p < 0.001 | |||
Positive | 121 | 57.9 % (70/121) | 42.1 % (51/121) | |
Negative | 105 | 17.1 % (18/105) | 82.9 % (87/105) | |
Progesterone receptor status | p < 0.001 | |||
Positive | 110 | 56.4 % (62/110) | 43.6 % (48/110) | |
Negative | 116 | 22.4 % (26/116) | 77.6 % (90/116) | |
Her2 | p < 0.05 | |||
Positive | 50 | 24 % (12/50) | 76 % (38/50) | |
Negative | 176 | 43.2 % (76/176) | 56.8 % (100/176) | |
Ki67 | p < 0.001 | |||
<14 % | 74 | 74.3 % (55/74) | 25.7 % (19/74) | |
14–30 % | 73 | 31.5 % (23/73) | 68.5 % (50/73) | |
>30 % | 79 | 12.7 % (10/79) | 87.3 % (69/79) | |
T stage | ||||
T1 | 105 | 33.3 % (35/105) | 66.7 % (70/105) | p > 0.05 |
T2 | 108 | 42.6 % (46/108) | 57.4 % (62/108) | |
T3 | 13 | 53.8 % (7/13) | 46.2 % (6/13) | |
Lymph node metastasis | p > 0.05 | |||
N0 | 94 | 38.3 % (36/94) | 61.7 (58/94) | |
N1 | 64 | 37.5 % (24/64) | 62.5 % (40/64) | |
N2 | 39 | 41 % (16/39) | 59 % (23/39) | |
N3 | 29 | 41.4 % (12/29) | 58.6 % (17/29) | |
Nuclear grade | p < 0.05 | |||
1 | 26 | 61.5 % (16/26) | 38.5 % (10/26) | |
2 | 86 | 43 % (37/86) | 57 % (49/86) | |
3 | 114 | 30.7 % (35/114) | 69.3 % (79/114) | |
H3K27me3 | p > 0.5 | |||
Positive | 220 | 39 % (86/220) | 61 % (134/220) | |
Negative | 6 | 33.3 % (2/6) | 66.7 % (4/6) | |
Total | 226 | 38.9 % (88/226) | 61.1 % (138/226) | |